Xenon Pharmaceuticals Inc (XENE) was Initiated by Guggenheim to “Buy” and the brokerage firm has set the Price Target at $20. Guggenheim advised their investors in a research report released on Sep 26, 2016.
Xenon Pharmaceuticals Inc closed down -0.02 points or -0.25% at $8 with 31,995 shares getting traded on Thursday. Post opening the session at $8.01, the shares hit an intraday low of $7.95 and an intraday high of $8.02 and the price fluctuated in this range throughout the day.Shares ended Thursday session in Red.
In a different news, on Aug 23, 2016, Frank A Holler (director) sold 11,938 shares at $7.65 per share price. According to the SEC, on Jun 28, 2016, Ian Mortimer (CFO) purchased 5,300 shares at $6.20 per share price. On Sep 24, 2015, Y. Paul Goldberg (VP of Clinical Development) sold 22,149 shares at $8.98 per share price, according to the Form-4 filing with the securities and exchange commission.
Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company discovering and developing a pipeline of differentiated therapeutics for orphan indications. The Company has built a core platform Extreme Genetics enabling the discovery of validated drug targets by studying rare human diseases with extreme traits including diseases caused by mutations in ion channels known as channelopathies. Its product pipeline includes Glybera which is a gene therapy approved in the EU for the treatment of patients with the orphan lipid disorder LPLD; TV-45070 which is a small-molecule inhibitor of the sodium channel Nav1.7; GDC-0276 which is a selective oral Nav1.7 small-molecule inhibitor being developed for the treatment of pain and XEN801 which is a selective small molecule inhibitor of SCD1 being developed for the treatment of dermatological disorders. FDA has granted fast track designations to TV-45070 for EM and to Glybera for LPLD and received orphan drug designation.